Nubain

Nu·bain (nbn)

A trademark for the drug nalbuphine hydrochloride.

---

nalbuphine hydrochloride

Nubain

Pharmacologic class: Opioid agonist-antagonist

Therapeutic class: Analgesic, adjunct to anesthesia

Pregnancy risk category C

Action

Binds to opiate receptors in CNS, inhibiting ascending pain pathways. This inhibition alters perception of and response to painful stimuli.

Availability

Injection: 10 mg/ml, 20 mg/ml

⊘Indications and dosages

➣ Moderate to severe pain

Adults: 10 mg/70 kg I.V., I.M., or subcutaneously q 3 to 6 hours p.r.n., up to 160 mg/day. Maximum for single dose is 20 mg.

➣ Adjunct to balanced anesthesia

Adults: 0.3 mg to 3 mg/kg I.V. over 10 to 15 minutes, followed by maintenance dose of 0.25 mg to 0.50 mg/kg I.V. in single doses p.r.n.

Contraindications

• Hypersensitivity to drug

Precautions

Use cautiously in:
• increased intracranial pressure, head trauma, myocardial infarction, severe heart disease, respiratory depression, renal or hepatic disease, impaired ventilation, hypothyroidism, adrenal insufficiency, prostatic hypertrophy, emotional instability, alcoholism
• history of substance abuse or dependence
• pregnant or breastfeeding patients
• children.

Administration

☞ Make sure emergency resuscitation equipment and naloxone (antidote) are available before starting therapy.
• For I.M. use, inject deep into large muscle mass; rotate injection sites.
• When giving I.V. for pain, infuse undiluted over 2 to 3 minutes into vein or I.V. line with compatible solution (such as dextrose 5% in water, normal saline solution, or lactated Ringer's solution).

Route	Onset	Peak	Duration
I.V.	2-3 min	30 min	3-6 hr
I.M.	15 min	1 hr	3-6 hr
Subcut.	15 min	Unknown	3-6 hr

Adverse reactions

CNS: dizziness, sedation, headache, vertigo

CV: hypertension, hypotension, tachycardia, bradycardia

EENT: miosis

GI: nausea, vomiting, dry mouth

Respiratory: dyspnea, respiratory depression

Skin: sweating, clammy skin

Other: hypersensitivity reactions including anaphylaxis

Interactions

Drug-drug. CNS depressants (including general anesthetics, MAO inhibitors, sedative-hypnotics, tranquilizers, tricyclic antidepressants): additive CNS effects

Drug-diagnostic tests. Amylase, lipase: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: additive CNS and respiratory depression

Patient monitoring

• Monitor vital signs. Watch for respiratory depression and heart rate changes.
• Evaluate patient for CNS changes. Institute safety measures as needed to prevent injury.
☞ Watch for hypersensitivity reactions, including anaphylaxis.

Patient teaching

• Instruct patient to change position slowly and carefully to avoid dizziness from sudden blood pressure decrease.
• Tell patient to avoid CNS depressants (including alcohol, sedative-hypnotics, and some herbs) for at least 24 hours after taking nalbuphine.
• Advise patient to consult prescriber before taking herbs.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.